omeprazole has been researched along with Polyarthritis in 15 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Excerpt | Relevance | Reference |
---|---|---|
"To compare the safety and efficacy of celecoxib versus diclofenac slow release (SR) plus omeprazole in elderly arthritis patients." | 9.16 | Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial. ( Essex, MN; Kellner, HL; Li, C, 2012) |
"In order to discover and develop drug-like anti-inflammatory agents against arthritis, based on "Hit" we found earlier and to overcome drawbacks of toxicity, twelve series of total 89 novel pyrimidine, pyrazolo[4,3-d]pyrimidine and thieno[3,2-d]pyrimidine derivatives were designed, synthesized and screened for their anti-inflammatory activity against NO and toxicity for normal liver cells (LO2)." | 8.02 | Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis. ( Chen, LZ; Huang, X; Liu, MM; Liu, XH; Ma, D; Shi, JB; Shu, HY; Wu, J; Yu, YL, 2021) |
"To compare the safety and efficacy of celecoxib versus diclofenac slow release (SR) plus omeprazole in elderly arthritis patients." | 5.16 | Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial. ( Essex, MN; Kellner, HL; Li, C, 2012) |
"A combination package containing delayed-release capsules of the proton pump inhibitor lansoprazole (15 mg once daily) and tablets of the NSAID naproxen (375 or 500 mg twice daily) has been approved for reducing the risk of NSAID-associated gastric ulcers in NSAID-requiring patients with a documented history of gastric ulcer." | 4.82 | Delayed-release lansoprazole plus naproxen. ( Curran, MP; Wellington, K, 2004) |
"In order to discover and develop drug-like anti-inflammatory agents against arthritis, based on "Hit" we found earlier and to overcome drawbacks of toxicity, twelve series of total 89 novel pyrimidine, pyrazolo[4,3-d]pyrimidine and thieno[3,2-d]pyrimidine derivatives were designed, synthesized and screened for their anti-inflammatory activity against NO and toxicity for normal liver cells (LO2)." | 4.02 | Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis. ( Chen, LZ; Huang, X; Liu, MM; Liu, XH; Ma, D; Shi, JB; Shu, HY; Wu, J; Yu, YL, 2021) |
"Cumulative recurrence rates at six months did not statistically differ among the three different groups (27% in H pylori negative, 46% in H pylori positive, and 31% in those where H pylori was eradicated during the healing phase), although a numerical trend in favour of a higher recurrence rate in infected patients was evident." | 2.68 | Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy. ( Bianchi Porro, G; Caruso, I; Imbesi, V; Montrone, F; Parente, F, 1996) |
"Treatment with omeprazole once daily has been shown to be superior to that with ranitidine and misoprostol in this respect." | 1.30 | Quality of life in arthritis patients using nonsteroidal anti-inflammatory drugs. ( Wiklund, I, 1999) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (20.00) | 18.2507 |
2000's | 9 (60.00) | 29.6817 |
2010's | 2 (13.33) | 24.3611 |
2020's | 1 (6.67) | 2.80 |
Authors | Studies |
---|---|
Chen, LZ | 1 |
Shu, HY | 1 |
Wu, J | 1 |
Yu, YL | 1 |
Ma, D | 1 |
Huang, X | 1 |
Liu, MM | 1 |
Liu, XH | 1 |
Shi, JB | 1 |
Blackler, R | 1 |
Syer, S | 1 |
Bolla, M | 1 |
Ongini, E | 1 |
Wallace, JL | 1 |
Kellner, HL | 1 |
Li, C | 1 |
Essex, MN | 1 |
Chan, FK | 4 |
Hung, LC | 2 |
Suen, BY | 2 |
Wu, JC | 3 |
Lee, KC | 1 |
Leung, VK | 1 |
Hui, AJ | 2 |
To, KF | 3 |
Leung, WK | 3 |
Wong, VW | 2 |
Chung, SC | 2 |
Sung, JJ | 3 |
Graham, DY | 1 |
Maev, IV | 1 |
V'iuchnova, ES | 1 |
Staseva, IV | 1 |
Curran, MP | 1 |
Wellington, K | 1 |
Lee, YT | 1 |
Cryer, B | 1 |
Spiegel, BM | 1 |
Chiou, CF | 1 |
Ofman, JJ | 1 |
Peura, D | 1 |
Wilcox, CM | 1 |
Niculescu, L | 1 |
Berger, M | 1 |
Beutler, M | 1 |
Hartmann, K | 1 |
Kuhn, M | 1 |
Gartmann, J | 1 |
Bianchi Porro, G | 1 |
Parente, F | 1 |
Imbesi, V | 1 |
Montrone, F | 1 |
Caruso, I | 1 |
Wiklund, I | 1 |
Yung, MY | 1 |
Kwok, T | 1 |
Hui, Y | 1 |
Chan, HL | 1 |
Chan, CS | 1 |
Hui, E | 1 |
Woo, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain[NCT00365976] | Phase 4 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe. (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
Intervention | units on a scale (Mean) | ||||
---|---|---|---|---|---|
prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 6.45 | 6.38 | 4.54 | 4.14 | 2.62 |
Placebo | 7.10 | 6.57 | 5.53 | 5.07 | 6.21 |
The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia). (NCT00365976)
Timeframe: Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4
Intervention | units on a scale (Mean) | ||||
---|---|---|---|---|---|
Prenaprosyn Baseline | Postnaprosyn baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 18.85 | 18.00 | 11.28 | 10.61 | 8.38 |
Placebo | 20.26 | 16.78 | 12.85 | 12.74 | 13.75 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
Intervention | minutes (Mean) | |||
---|---|---|---|---|
Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 38.28 | 22.36 | 17.50 | 15.28 |
Placebo | 34.11 | 27.00 | 23.10 | 19.91 |
Nightly total sleep time was averaged from diary entries. (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, week 2, week 4
Intervention | Minutes (Mean) | |||
---|---|---|---|---|
postnaprosyn baseline | week 1 | week 2 | Week 4 | |
Eszopiclone | 316.96 | 403.47 | 421.97 | 411.97 |
Placebo | 380.45 | 375.56 | 382.11 | 388.96 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
Intervention | awakenings (Mean) | |||
---|---|---|---|---|
Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 2.29 | 1.31 | 1.35 | 1.33 |
Placebo | 2.08 | 1.98 | 2.13 | 2.34 |
Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain) (NCT00365976)
Timeframe: postnaprosyn Baseline, Week 1, Week 2 week 4
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 4.02 | 3.54 | 3.30 | 3.08 |
Placebo | 3.90 | 3.82 | 4.01 | 3.80 |
"The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 yes-no items assessing potential disabilities.~Scores range from 0 (no disability) to 24 (severe disability)." (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
Intervention | units on a scale (Mean) | ||||
---|---|---|---|---|---|
prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 12.27 | 9.97 | 9.10 | 7.63 | 6.59 |
Placebo | 11.33 | 10.30 | 9.05 | 9.32 | 7.94 |
Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep (NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 4.52 | 5.99 | 6.18 | 6.38 |
Placebo | 4.44 | 4.90 | 5.33 | 5.29 |
Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, Week 2, Week 4
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 48.51 | 40.72 | 34.70 | 31.69 |
Placebo | 53.79 | 51.99 | 51.25 | 51.60 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
Intervention | minutes (Mean) | |||
---|---|---|---|---|
Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
Eszopiclone | 91.51 | 49.34 | 37.07 | 36.74 |
Placebo | 81.43 | 76.71 | 81.32 | 76.18 |
2 reviews available for omeprazole and Polyarthritis
Article | Year |
---|---|
Delayed-release lansoprazole plus naproxen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2004 |
Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin | 2005 |
6 trials available for omeprazole and Polyarthritis
Article | Year |
---|---|
Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2 Inhibitors; Di | 2012 |
Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2002 |
[Comparative efficacy of different therapeutic schemes in gastropathies induced by nonsteroid anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Drug Administration Schedule; | 2004 |
Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Topics: Adult; Aged; Arthritis; Celecoxib; Diclofenac; Double-Blind Method; Drug Therapy, Combination; Dyspe | 2004 |
Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy.
Topics: Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Drug Therapy, Co | 1996 |
Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Delayed-Action Preparations; | 2002 |
7 other studies available for omeprazole and Polyarthritis
Article | Year |
---|---|
Discovery and development of novel pyrimidine and pyrazolo/thieno-fused pyrimidine derivatives as potent and orally active inducible nitric oxide synthase dimerization inhibitor with efficacy for arthritis.
Topics: Administration, Oral; Animals; Arthritis; Cells, Cultured; Dimerization; Disease Models, Animal; Dos | 2021 |
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combi | 2012 |
NSAIDs, Helicobacter pylori, and Pandora's Box.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Cyclooxygenase 2; | 2002 |
COX-2-specific inhibitor or proton pump inhibitor plus traditional NSAID: is either approach sufficient for patients at highest risk of NSAID-induced ulcers?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Cyclooxygenase 2; Cyclooxyge | 2004 |
Response to Ray and colleagues: the called-for large clinical trial is already ongoing.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Celecoxib; Diclofenac; Humans | 2008 |
Arthralgias and omeprazole.
Topics: Adult; Aged; Arthralgia; Arthritis; Erythema Nodosum; Female; Humans; Male; Middle Aged; Omeprazole | 1994 |
Quality of life in arthritis patients using nonsteroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis; Female; Humans; Male; M | 1999 |